Context Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $22.69M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Dec 31, 2022 | Mar 22, 2023 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 23, 2022 | During market hours | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Dec 2, 2021 | During market hours | – | – | – |
Press releases
Announcements Context Therapeutics filed with the SEC
August 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
June 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
June 15, 2026 Phase 1 Interim Results CTIM-76: A Novel CLDN6 x CD3 TCE
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
March 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
January 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
November 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
December 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Exhibit 99.1
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
September 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
July 2024 Corporate Presentation Advancing Medicines for Solid Tumors
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Context Therapeutics Announces $100 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
May 2024 Corporate Presentation Advancing Medicines for Solid Tumors
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
March 2024 Corporate Presentation Advancing Medicines for Solid Tumors
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
November 2023 Corporate Presentation Advancing Medicines for Solid Tumors
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
August 2023 Corporate Presentation Advancing Medicines for Solid Tumors
Regulation FD disclosure · EX-99.1 to Form 8-K
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Results of operations · Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
March 2023 Corporate Presentation Advancing Medicines for Solid Tumors
Results of operations · Exit or restructuring costs · Regulation FD disclosure · EX-99.2 to Form 8-K
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
February 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors
Regulation FD disclosure · EX-99.2 to Form 8-K
Context Therapeutics ® Highlights 2023 Corporate Priorities and Pipeline Milestones
Regulation FD disclosure · EX-99.1 to Form 8-K
January 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors
Regulation FD disclosure · EX-99.2 to Form 8-K
Context Therapeutics ® Reports Encouraging Preliminary Phase 2 Data for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Context Therapeutics ® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
December 1, 2022 Identification of CTIM-76, a CLDN6 x CD3 bispecific antibody
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
November 2022 Corporate Presentation Advancing Medicines for Female Cancers
Regulation FD disclosure · EX-99.1 to Form 8-K
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
September 2022 Corporate Presentation Advancing Medicines for Female Cancers
Regulation FD disclosure · EX-99.2 to Form 8-K